Patents by Inventor Natalia Lukasiewicz

Natalia Lukasiewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Influenza virus hemagglutinin protein as a vaccine antigen
    Patent number: 10398770
    Abstract: The invention relates to an influenza viruses hemagglutinin protein as a vaccine antigen against influenza viruses, in particular to a protein being a fragment of H5 hemagglutinin from highly pathogenic avian influenza virus (HPAIV) H5N1 strain, expressed in a bacterial expression system. The protein according to the invention is a potential ingredient of an anti-HPAIV H5N1 vaccine, administered to chickens parenterally or through mucous membranes in the presence of adjuvants. The object of the invention is also a method of obtaining the vaccine protein.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: September 3, 2019
    Assignee: INSTYTUT BIOTECHNOLOGII I ANTY-BIOTYKOW
    Inventors: Violetta Sączyńska, Agnieszka Romanik, Katarzyna Florys, Violetta Cecuda-Adamczewska, Malgorzata Kęsik-Brodacka, Grażyna Plucienniczak, Andrzej Plucienniczak, Piotr Borowicz, Natalia Lukasiewicz, Iwona Sokolowska, Diana Mikiewicz, Agnieszka Sobolewska, Piotr Baran, Józef Kapusta, Michal Odrowąż-Sypniewski, Anna Bierczy{dot over (n)}ska-Krzysik, Zenon Minta, Krzysztof Śmietanka, Monika Olszewska, Boguslaw Szewczyk
  • Influenza Virus Hemagglutinin Protein as a Vaccine Antigen
    Publication number: 20170165352
    Abstract: The invention relates to an influenza viruses hemagglutinin protein as a vaccine antigen against influenza viruses, in particular to a protein being a fragment of H5 hemagglutinin from highly pathogenic avian influenza virus (HPAIV) H5N1 strain, expressed in a bacterial expression system. The protein according to the invention is a potential ingredient of an anti-HPAIV H5N1 vaccine, administered to chickens parenterally or through mucous membranes in the presence of adjuvants. The object of the invention is also a method of obtaining the vaccine protein.
    Type: Application
    Filed: June 24, 2015
    Publication date: June 15, 2017
    Applicant: INSTYTUT BIOTECHNOLGII ANTY-BIOTYKOW
    Inventors: Violetta SACZYNSKA, Agnieszka ROMANIK, Katarzyna FLORYS, Violetta CECUDA-ADAMCZEWSKA, Malgorzata KESIK-BRODACKA, Grazyna PLUCIENNICZAK, Andrzej PLUCIENNICZAK, Piotr BOROWICZ, Natalia LUKASIEWICZ, Iwona SOKOLOWSKA, Diana MIKIEWICZ, Agnieszka SOBOLEWSKA, Piotr BARAN, Józef KAPUSTA, Michal ODROWAZ-SYP-NIEWSKI, Anna BIERCZYNSKA-KRZYSIK, Zenon MINTA, Krzysztof SMIETANKA, Monika OLSZEWSKA, Boguslaw SZEWCZYK
  • Insulin Analogue Or Its Pharmaceutically Acceptable Salt, Pharmaceutical Composition With Prolonged Therapeutic Effect, Use Of The Insulin Analogue, Dosage Method and Method of Treatment of Diabetes
    Publication number: 20150164998
    Abstract: The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable insulin analogues which are pharmaceutically active and characterised by a prolonged, flat, truly peakless course of glucose concentration vs. time during repeated administration and which do not show strong 24 hours fluctuations of glucose concentration, or the so-called “sawteeth effect”, during this time. Results of studies of compounds included in the scope of this application indicate an improvement in the effects of diabetes treatment by avoiding the hitherto occurring adverse influence of changes in glucose concentration throughout the entire day on a patient's organism, e.g.
    Type: Application
    Filed: May 22, 2013
    Publication date: June 18, 2015
    Applicant: INSTYTUT BIOTECHNOLOGII I ANTYBIOTYKOW
    Inventors: Piotr Borowicz, Andrzej Plucienniczak, Jerzy Mikolajczyk, Jaroslaw Antosik, Jacek Pstrzoch, Justyna Bernat, Diana Mikiewicz-Sygula, Monika Bogiel, Dorota Stadnik, Grazyna Plucienniczak, Bozena Tejchman-Malecka, Tadeusz Glabski, Iwona Sokolowska, Dariusz Kurzynoga, Anna Wojtowicz-Krawiec, Marcin Zielinski, Malgorzata Kesik-Brodacka, Natalia Lukasiewicz
  • Method for production of recombinant growth hormone in form of hybrid protein
    Patent number: 7892787
    Abstract: A method of producing somatotropin encompassing the microbiological expression of a recombinant protein containing somatotropin and hybrid polypeptide containing the amino-acid sequence of ubiquitin and the amino-acid sequence of somatotropin.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: February 22, 2011
    Assignee: Instytut Biotechnologii I Antybiotykow
    Inventors: Andrzej Plucienniczak, Maria Ludwika Smorawinska, Renata Wolinowska, Diana Mikiewicz-Sygula, Iwona Sokolowska, Natalia Lukasiewicz, Luiza Chojnacka, Grazyna Plucienniczak, Jolanta Kuthan-Styczen, Krystyna Strzezek, Alina Marciniak-Rusek, Anna Kruszynska, Anna Wojtowicz, Anna Mazurkiewicz-Pisarek, Ewa Wojcik
  • Method for production of recombinant growth hormone in form of hybrid protein
    Publication number: 20080160570
    Abstract: A method of producing somatotropin encompassing the microbiological expression of a recombinant protein containing somatotropin and hybrid polypeptide containing the amino-acid sequence of ubiquitin and the amino-acid sequence of somatotropin.
    Type: Application
    Filed: July 7, 2006
    Publication date: July 3, 2008
    Inventors: Andrzej Plucienniczak, Maria Ludwika Smorawinska, Renata Wolinowska, Diana Mikiewicz-Sygula, Iwona Sokolowska, Natalia Lukasiewicz, Luiza Chojnacka, Grazyna Plucienniczak, Jolanta Kuthan-Styczen, Krystyna Strzezek, Alina Marciniak-Rusek, Anna Kruszynska, Anna Wojtowicz, Anna Mazurkiewicz-Pisarek, Ewa Wojcik